Clinical trials: Injection Complication
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03666923
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Postsurgical Pain
A Trial of SHR0410 Injection in Postsurgical Pain Management
The study is being conducted to evaluate the efficacy, safety of SHR0410 Injection and to explore the reasonable of SHR0410 Injection for Pain Management after Orthopaedic Surgery.
- Trial name
- NCT05394402
- Testing
- SHR0410 Injection
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Primary Hyperoxaluria
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH).
- Trial name
- NCT03392896
- Testing
- DCR-PHXC
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Peripheral Arterial Disease, Diabetic Foot
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of intramuscular administration of human placenta-derived cells (PDA-002) in subjects with…
- Trial name
- DFU-002 (NCT02264288)
- Testing
- PDA-002
- Where
- 45 sites in United States
- Volunteers
- 159 people
- Sponsor
- Celularity Incorporated
Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation…
- Conditions
- Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer
- Trial name
- EVOLVE (NCT02028442)
- Testing
- Enadenotucirev
- Where
- 6 sites in Belgium, Spain
- Volunteers
- 61 people
- Sponsor
- Akamis Bio
Peripheral Arterial Disease(PAD), Arterial Occlusive Disease
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
The goal of this observational study is to learn about the long-term effects of Donaperminogene Seltoplasmid Injection (NL003) in participants who have been received drug NL003 or placebo at least one dose from the parent phase…
- Conditions
- Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans
- Trial name
- NCT07023965
- Testing
- NL003
- Where
- 5 sites in China
- Volunteers
- 542 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Postoperative Pain
Pilot Herniorrhaphy Study for Postoperative Analgesia
A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal…
- Trial name
- NCT02504580
- Testing
- HTX-011, HTX-002, Bupivacaine HCI (Marcaine)
- Where
- 3 sites in United States
- Volunteers
- 463 people
- Sponsor
- Heron Therapeutics
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
Postoperative Pain
Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty
The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral…
- Trial name
- NCT01683071
- Testing
- EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
- Where
- 30 sites in United States
- Volunteers
- 297 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Chronic Kidney Disease, Secondary Hyperparathyroidism
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK) in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Trial name
- NCT00742716
- Testing
- CTA018 Injection
- Where
- 12 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- OPKO IP Holdings II, Inc.
Complicated Urinary Tract Infection, Acute Pyelonephritis
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
This was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary…
- Trial name
- NCT01096849
- Testing
- levofloxacin, plazomicin
- Volunteers
- 145 people
- Sponsor
- Achaogen, Inc.
Pain, Postoperative
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores
This is a multiple center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with high Pain Catastrophizing Scale…
- Trial name
- NCT04104919
- Testing
- Brivoligide Injection 660 mg/6 mL
- Sponsor
- Adynxx, Inc.
Heart Failure, Congestive
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00328692
- Testing
- rolofylline
- Volunteers
- 932 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy, Renal Impairment
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
This study is open to adults aged between 18 and 80 years of age with a body mass index (BMI) of 20 to 40 kg/m2. People with or without kidney problems can take part in the study.
- Trial name
- NCT06352411
- Testing
- BI 456906
- Where
- 2 sites in Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer Recurrent
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .
- Trial name
- NCT03681548
- Testing
- Doxorubicin Hydrochloride Liposome Injection
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Ayana Pharma Ltd.,
Chronic Kidney Disease
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
- Trial name
- NCT01469078
- Testing
- Monofer®
- Volunteers
- 18 people
- Sponsor
- Pharmacosmos A/S
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
The purpose of this study is to evaluate the effects of Zemplar® Injection and Hectorol® Injection on intestinal calcium absorption in Chronic Kidney Disease Stage 5 subjects on hemodialysis.
- Trial name
- NCT00257920
- Testing
- Zemplar® injection, Hectorol® injection
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Abbott
Interstitial Cystitis, Bladder Pain Syndrome
PK and Safety of SI-722 in IC/BPS
This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.
- Trial name
- NCT04208087
- Testing
- SI-722
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seikagaku Corporation